Overview

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

Status:
Recruiting

Trial end date:
2023-07-30

Target enrollment:

Participant gender:

Summary

This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care (Intralipid) from 7 up to 90 days to develop Essential Fatty Acid Deficiency (EFAD). Additionally, this study design will evaluate the safety and efficacy of using Clinolipid or Intralipid in a pediatric population.

Phase:

Phase 4

Details

Lead Sponsor:

Baxter Healthcare Corporation

Treatments:

Soybean oil, phospholipid emulsion